the RSV virion structure, key neutralizing epitopes on the pre- and post-fusion forms of the fusion protein and implications for vaccine development. CHF: Congestive heart failure; CLD ...

Future Virology. 2014;9(8):753-767. CHF: Congestive heart failure; CLD: Chronic lung disease; F: Fusion; G: Glyco; GLA-SE: Glucopyranosyl lipid A-stable emulsion; GMT ...

the prevention of LRTD caused by RSV in people 18 through 59 years of age who are at increased risk for LRTD caused by RSV pregnant individuals at 32 through 36 weeks gestational age for the ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices ...

In the prefusion state, the RSV fusion protein (F) is a major target of neutralizing antibodies, serving as the basis of Pfizer’s RSV vaccine. Variations in the F protein sequence among RSV-A ...

In the prefusion state, the RSV fusion protein (F) is a major target of neutralizing antibodies, serving as the basis of Pfizer’s RSV vaccine. Variations in the F protein sequence among RSV-A ...

AK0610 is engineered from an antibody isolated from a recovered infant and targets the pre-fusion F protein of RSV. It has a unique viral antigen binding epitope and a new mechanism of action.

The acquisition focuses on sisunotavir, an RSV fusion inhibitor that UK-based ReViral ... including a follow-up RSV candidate targeting the viral N protein that is in phase 1 testing.